<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28605">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02146716</url>
  </required_header>
  <id_info>
    <org_study_id>2013-840</org_study_id>
    <nct_id>NCT02146716</nct_id>
  </id_info>
  <brief_title>Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.</brief_title>
  <acronym>RESC</acronym>
  <official_title>Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of RESC study is to assess the efficacy of Energetic Resonance by Cutaneous
      Stimulation on alcohol withdrawal symptoms measured by CUSHMAN score and in a second time to
      measure the benzodiazepine amount prescribed during the withdrawal time.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Cushman Score measure after Energetic Resonance by Cutaneous Stimulation</measure>
    <time_frame>daily during one week</time_frame>
    <safety_issue>No</safety_issue>
    <description>CUSHMAN score is represented by a scale with 7 variables collecting physiological modifications or behavioural manifestations related to adrenergic answer, neurovegetative signs, confusion, nervousness, perceptive or hallucinatory phenomena.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety depression scale</measure>
    <time_frame>pre-screening, day 3 and day 7</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prescribed benzodiazepine amount</measure>
    <time_frame>day 0 to day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analogic Visual Scale</measure>
    <time_frame>before and after each Energetic Resonance by Cutaneous Stimulationsession at day 2, day 4 and day 6.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life scale</measure>
    <time_frame>day 0</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alcohol Withdrawal Syndrome</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Energetic Resonance by Cutaneous Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Energetic Resonance by Cutaneous Stimulation</intervention_name>
    <description>Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.</description>
    <arm_group_label>Energetic Resonance by Cutaneous Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women between 18 and 80 years,

          -  Patient with alcohol addiction,

          -  Patient needing alcohol withdrawal in a hospital.

          -  Patient with social Security,

          -  Patient with inform consent signed.

        Exclusion Criteria:

          -  Pregnant women

          -  Minor.

          -  Major with guardianship.

          -  People without sufficient information because of troubles of cognitive functions, or
             without sufficient knowledge of French language.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claude Augustin-Normand, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claude Augustin Normand, Dr</last_name>
    <phone>4.27.73.26.01</phone>
    <phone_ext>+33</phone_ext>
    <email>claude.augustin-normand@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle Delfour</last_name>
    <phone>4.26.73.27.25</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.delfour@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital croix rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claude Augustin-Normand, Dr</last_name>
      <phone>4.27.73.26.01</phone>
      <phone_ext>+33</phone_ext>
      <email>claude.augustin-normand@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Augustin-Normand, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RESC, alcohol withdrawal syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance Withdrawal Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
